Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
MRKR - Marker Therapeutics, Inc.
Market Cap 50.77M P/E - EPS this Y - Ern Qtrly Grth -
Income -10.31M Forward P/E -1.70 EPS next Y -2.10% 50D Avg Chg 45.00%
Sales 3.73M PEG - EPS past 5Y - 200D Avg Chg 102.00%
Dividend N/A Price/Book 3.19 EPS next 5Y - 52W High Chg -40.00%
Recommedations 1.50 Quick Ratio 5.22 Shares Outstanding 8.92M 52W Low Chg 761.00%
Insider Own 12.20% ROA -40.87% Shares Float 6.76M Beta 1.55
Inst Own 22.62% ROE -71.74% Shares Shorted/Prior 64.76K/81.05K Price 5.77
Gross Margin -156.82% Profit Margin -278.22% Avg. Volume 861,779 Target Price 11.75
Oper. Margin -197.40% Earnings Date Nov 7 Volume 217,337 Change 4.72%
Healthcare | Biotechnology | United States
About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Marker Therapeutics, Inc. News
12/19/24 Marker Therapeutics Announces $16.1 Million Private Placement
12/19/24 Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
12/17/24 Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
12/10/24 Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
12/06/24 Marker Therapeutics Leads 3 Noteworthy US Penny Stocks
11/26/24 Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
11/17/24 Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/14/24 Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/23/24 US Penny Stocks To Consider In October 2024
10/22/24 Marker Therapeutics price target raised to $19 from $11 at Ladenburg
09/26/24 AML cell therapy trials to watch in 2024 targeting GvHD
08/28/24 Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
08/14/24 Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
08/12/24 Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
07/18/24 Marker Therapeutics (NASDAQ:MRKR) shareholders are up 20% this past week, but still in the red over the last five years
05/15/24 Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
04/08/24 Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
04:45 PM Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
03/22/24 Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
01/22/24 Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Eansor Norman David Director Director Mar 16 Buy 17.5 14,285 249,988 16,713 06/08/23